Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

被引：9

作者：

Kahraman, Seda ^{[1
]}

Erul, Enes ^{[2
]}

Seyyar, Mustafa ^{[3
]}

Gumusay, Ozge ^{[4
]}

Bayram, Ertugrul ^{[5
]}

Demirel, Burcin Cakan ^{[6
]}

Acar, Omer ^{[7
]}

Aksoy, Sercan ^{[2
]}

Baytemur, Naziyet Kose ^{[8
]}

Sahin, Elif ^{[3
]}

Cabuk, Devrim ^{[3
]}

Basaran, Gul ^{[4
]}

Paydas, Semra ^{[5
]}

Yaren, Arzu ^{[6
]}

Guven, Deniz Can ^{[2
]}

Erdogan, Atike Pinar ^{[7
]}

Demirci, Umut ^{[8
]}

Yasar, Alper ^{[9
]}

Bayoglu, Ibrahim Vedat ^{[9
]}

Hizal, Mutlu ^{[1
]}

Gulbagci, Burcu ^{[10
]}

Paksoy, Nail ^{[11
]}

Davarci, Sena Ece ^{[12
]}

Yilmaz, Funda ^{[13
]}

Dogan, Ozlem ^{[14
]}

Orhan, Sibel Oyucu ^{[15
]}

Kayikcioglu, Erkan ^{[16
]}

Aytac, Ali ^{[17
]}

Keskinkilic, Merve ^{[18
]}

Mocan, Eda Eylemer ^{[19
]}

Unal, Olcun Umit ^{[20
]}

Aydin, Esra ^{[21
]}

Yucel, Hakan ^{[22
]}

Isik, Deniz ^{[23
]}

Eren, Onder ^{[24
]}

Uluc, Basak Oyan ^{[4
]}

Ozcelik, Melike ^{[25
]}

Hacibekiroglu, Ilhan ^{[10
]}

Aydiner, Adnan ^{[11
]}

Demir, Hacer ^{[12
]}

Oksuzoglu, Berna ^{[13
]}

Cilbir, Ebru ^{[14
]}

Cubukcu, Erdem ^{[15
]}

Cetin, Bulent ^{[16
]}

Oktay, Esin ^{[17
]}

Erol, Cihan ^{[1
]}

Okutur, Sadi Kerem ^{[26
]}

Yildirim, Nilgun ^{[27
]}

Alkan, Ali ^{[28
]}

Selcukbiricik, Fatih ^{[29
]}

机构：

[1] Ankara Yildirim Beyazit Univ, Ankara City Hosp, Dept Med Oncol, TR-06800 Ankara, Turkiye

[2] Hacettepe Univ, Canc Inst, Dept Med Oncol, TR-06590 Ankara, Turkiye

[3] Kocaeli Univ, Med Fac Hosp, Dept Med Oncol, TR-41000 Kocaeli, Turkiye

[4] Acibadem Univ, Sch Med, Dept Med Oncol, TR-34750 Istanbul, Turkiye

[5] Cukurova Univ, Dept Med Oncol, TR-01330 Adana, Turkiye

[6] Pamukkale Univ Hosp, Dept Med Oncol, TR-20160 Denizli, Turkiye

[7] Manisa Celal Bayar Univ Hosp, Dept Med Oncol, TR-45120 Mersin, Turkiye

[8] Ankara Mem Hosp, Dept Med Oncol, TR-06520 Ankara, Turkiye

[9] Marmara Univ, Dept Med Oncol, Pendik Res & Applicat Hosp, TR-34899 Istanbul, Turkiye

[10] Sakarya Univ, Sch Med, Dept Med Oncol, TR-54187 Sakarya, Turkiye

[11] Istanbul Univ, Dept Med Oncol, TR-34093 Istanbul, Turkiye

[12] Afyonkarahisar Hlth Sci Univ, Dept Med Oncol, TR-03200 Afyonkarahisar, Turkiye

[13] Dr Abdurrahman Yurtaslan Ankara Oncol Training & R, Dept Med Oncol, TR-06200 Ankara, Turkiye

[14] Ankara Etlik City Hosp, Dept Med Oncol, TR-06170 Ankara, Turkiye

[15] Uludag Univ, Dept Med Oncol, TR-16059 Bursa, Turkiye

[16] Suleyman Demirel Univ, Dept Med Oncol, TR-32260 Isparta, Turkiye

[17] Aydin Adnan Menderes Univ, Dept Med Oncol, Training & Res Hosp, TR-09100 Aydin, Turkiye

[18] Dokuz Eylul Univ, Res & Applicat Hosp, Dept Med Oncol, TR-35340 Izmir, Turkiye

[19] Ankara Univ, Dept Med Oncol, TR-06080 Ankara, Turkiye

[20] Tepecik Training & Res Hosp, Dept Med Oncol, TR-35180 Izmir, Turkiye

[21] Recep Tayyip Erdogan Univ Training & Res Hosp, Dept Med Oncol, TR-53020 Rize, Turkiye

[22] Gaziantep Univ, Dept Med Oncol, TR-27580 Gaziantep, Turkiye

[23] Kocaeli Med Pk Hosp, Dept Med Oncol, TR-41140 Kocaeli, Turkiye

[24] Selcuk Univ, Dept Med Oncol, Med Fac Hosp, TR-42250 Konya, Turkiye

[25] Umraniye Training & Res Hosp, Dept Med Oncol, TR-34764 Istanbul, Turkiye

[26] Istanbul Arel Univ, Bahcelievler Mem Hosp, Dept Med Oncol, TR-34537 Istanbul, Turkiye

[27] Firat Univ Hosp, Dept Med Oncol, TR-23200 Elazig, Turkiye

[28] Mugla Sitki Kocman Univ Training & Res Hosp, Dept Med Oncol, TR-48000 Mugla, Turkiye

[29] Koc Univ Hosp, Dept Med Oncol, TR-34010 Istanbul, Turkiye

[30] Elazig Fethi Sekin City Hosp, Dept Med Oncol, TR-23280 Elazig, Turkiye

[31] Acibadem Bodrum Hosp, Dept Med Oncol, TR-48420 Mugla, Turkiye

[32] Canakkale Onsekiz Mart Univ, Dept Med Oncol, Res & Practice Hosp, TR-17100 Canakkale, Turkiye

[33] Adana City Training & Res Hosp, Dept Med Oncol, TR-01230 Adana, Turkiye

[34] Kocaeli Derince Training & Res Hosp, Dept Med Oncol, TR-41310 Kocaeli, Turkiye

[35] Kahramanmaras Necip Fazil City Hosp, Dept Med Oncol, TR-46050 Kahramanmaras, Turkiye

[36] Necmettin Erbakan Univ, Dept Med Oncol, Meram Med Fac Hosp, TR-42080 Konya, Turkiye

[37] Gulhane Training & Res Hosp, Dept Med Oncol, TR-06010 Ankara, Turkiye

[38] Mersin City Hosp, Dept Med Oncol, TR-96015 Mersin, Turkiye

[39] Namik Kemal Univ, Dept Med Oncol, Hlth Applicat & Res Hosp, TR-59030 Tekirdag, Turkiye

[40] Van Yuzuncu Yil Univ, Dursun Odabas Hosp, Dept Med Oncol, TR-65090 Van, Turkiye

[41] Manisa City Hosp, Dept Med Oncol, TR-45040 Manisa, Turkiye

[42] Konya City Hosp, Dept Med Oncol, TR-42020 Konya, Turkiye

[43] Ordu State Hosp, Dept Med Oncol, TR-52200 Ordu, Turkiye

[44] Aydin Ataturk State Hosp, Dept Med Oncol, TR-09020 Aydin, Turkiye

[45] Izmir Bozyaka Training & Res Hosp, Dept Med Oncol, TR-35170 Izmir, Turkiye

[46] Anadolu Med Ctr, Dept Med Oncol, TR-34758 Istanbul, Turkiye

来源：

FUTURE ONCOLOGY | 2023年

关键词：

CDK; 4; 6; inhibitors; HER2-negative metastatic breast cancer; HR-positive; letrozole;

D O I：

10.2217/fon-2022-1287

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.

引用

页码：727 / 736

页数：10

共 50 条

[31] Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results
Fernandez-Cuerva, Cristina
Valencia, Juan Carlos del Rio
Tamayo Bermejo, Rocio
CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2022, 75 (01): : 26 - 33
[32] Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results
Fernandez-Cuerva, C.
Del Rio, Valencia J. C.
Bermejo, R. T.
CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2022, 75 (02): : 128 - 128
[33] First-line ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis
Tripathy, D.
Hortobagyi, G.
Chan, A.
Im, S-A
Chia, S.
Yardley, D.
Esteva, F. J.
Hurvitz, S.
Kong, O.
Bao, W.
Lorenc, K. Rodriguez
Diaz-Padilla, I.
Slamon, D. J.
CANCER RESEARCH, 2019, 79 (04)
[34] First-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2
Hortobagyi, Gabriel N.
Stemmer, Salomon
Campone, Mario
Sonke, Gabe S.
Arteaga, Carlos L.
Paluch-Shimon, Shani
Petrakova, Katarina
Villanueva, Cristian
Nusch, Arnd
Grischke, Eva-Maria
Chan, Arlene
Jakobsen, Erik
Marschner, Norbert
Hart, Lowell L.
Alba, Emilio
Ohnstand, Hege O.
Blau, Sibel
Yardley, Denise A.
Solovieff, Nadia
Su, Faye
Germa, Caroline
Yap, Yoon-Sim
CANCER RESEARCH, 2018, 78 (04)
[35] Phase Ib study of ribociclib plus letrozole in Asian non-Japanese patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESASIA
Yap, Yoon Sim
Ito, Yoshinori
Suarez-Vizcarra, Jose
Liu, Xiaochun
Han, Yu
Germa, Caroline
Chiu, Joanne
CANCER RESEARCH, 2018, 78 (04)
[36] Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
Abdel-Razeq, Hikmat
Sharaf, Baha
AlMasri, Rama
Abdel-Razeq, Rashid
Tanninni, Faris
Khader, Omar
Salanna, Osama
Abunasser, Mahmoud
Edaily, Sarah
Abdulelah, Hazem
CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1033 - 1041
[37] Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
Demir, Atakan
Mandel, Nil Molinas
Paydas, Semra
Demir, Gokhan
Er, Ozlem
Turhal, Nazim Serdal
Bavbek, Sevil
Eralp, Yesim
Saip, Pinar Mualla
Guler, Emine Nilufer
Aydiner, Adnan
Uluc, Basak Oyan
Kilickap, Sadettin
Uskent, Necdet
Karadurmus, Nuri
Kaplan, Mehmet Ali
Yanmaz, Mustafa Teoman
Demir, Hacer
Alan, Ozkan
Korkmaz, Taner
Olgun, Polat
Uysal, Ozlem Sonmez
Altundag, Kadri
Gunduz, Seyda
Gunaldi, Meral
Sari, Murat
Beypinar, Ismail
Basaran, Gul
BALKAN MEDICAL JOURNAL, 2020, 37 (02) : 104 - 107
[38] Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib plus letrozole vs placebo plus letrozole in the phase III MONALEESA-2 study
Blackwell, Kimberly L.
Paluch-Shimon, Shani
Campone, Mario
Conte, Pierfranco
Petrakova, Katarina
Favret, Anne
Blau, Sibel
Beck, J. Thaddeus
Miller, Michelle
Sutradhar, Santosh
Monaco, Mauricio
Burris, Howard A.
CANCER RESEARCH, 2018, 78 (04)
[39] FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Gao, Jennifer J.
Osgood, Christy L.
Feng, Zhou
Bloomquist, Erik W.
Tang, Shenghui
Chang, C. J. George
Ricks, Tiffany K.
Hou, Sherry C.
Pierce, William F.
Rivera, Donna R.
Pazdur, Richard
Kluetz, Paul G.
Amiri-Kordestani, Laleh
CLINICAL CANCER RESEARCH, 2023, 29 (24) : 5008 - 5011
[40] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Lim, Bora
Potter, David A.
Salkeni, Mohamad A.
Silverman, Paula
Haddad, Tufia C.
Forget, Frederic
Awada, Ahmad
Canon, Jean-Luc
Danso, Michael
Lortholary, Alain
Bourgeois, Hugues
Tan-Chiu, Elizabeth
Vincent, Sylvie
Bahamon, Brittany
Galinsky, Kevin J.
Patel, Chirag
Neuwirth, Rachel
Leonard, E. Jane
Diamond, Jennifer R.
CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338

← 1 2 3 4 5 →